15-min delayed · Sep 8, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 8 firms covering Arcturus Therapeutics Holdings Inc, 6 rate it Buy or better, 2 sit at Hold, and 0 rate it Sell or worse, a moderate buy consensus. The target range is very wide, $9.00 to $27.00 (about 3.0x), which points to deep disagreement over how to value the company rather than near-term timing. The average target of $21.00 sits 34% above the current $15.62. The rating mix has stayed broadly stable, with Buy-side ratings easing from 7 to 6 over recent months. On the fundamentals, the Street sees revenue growth near -53% this year and 10% next, consensus EPS building from about $-0.90 next quarter toward $-3.61 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS8 ratings
Moderate Buy
Strong Buy00%
Buy675%
Hold225%
Sell00%
Strong Sell00%
Based on 8 analysts giving stock ratings to Arcturus Therapeutics Holdings Inc.
As of Sep, 6 of 8 firms rate ARCT a Buy (2 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
ARCT EPS & revenue forecast
EPS · NEXT QUARTER
$-0.90
Range $-1.55 – $-0.26 · 10 analysts · -12% YoY
Next period, 10 analysts expect Arcturus Therapeutics Holdings Inc to earn $-0.90 a share (range $-1.55 – $-0.26), versus $-1.03 a year earlier. Full-year consensus is $-3.42, growing to $-3.61 the year after.
REVENUE · NEXT QUARTER
$5.7M
Range $1.9M – $19.7M · 10 analysts · -61% YoY
Revenue is expected to reach $5.7M (range $1.9M – $19.7M), -61.0% year-over-year. Full-year consensus is $18.6M, rising to $29.6M next year.
Top analysts covering Arcturus Therapeutics Holdings Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on ARCT.
#1
Mayank Mamtani
B. Riley Securities · Rank #41
Buy
$22.00+40.8% to target
Overall win rate
50%
+ Follow
#2
Andrew Fein
HC Wainwright & Co. · Rank #55
Hold
$9.00-42.4% to target
Overall win rate
46%
+ Follow
#3
Ed Arce
HC Wainwright & Co. · Rank #132
Buy
$60.00+284.1% to target
Overall win rate
44%
+ Follow
#4
Josh Schimmer
Cantor Fitzgerald · Rank #162
Buy
No targeton ARCT
Overall win rate
38%
+ Follow
#5
Greg Harrison
Scotiabank · Rank #179
Buy
$35.00+124.1% to target
Overall win rate
38%
+ Follow
ARCT stock forecast FAQ
What is ARCT's average 12-month price target?+
The 7 analysts with a live target average $21.00 for Arcturus Therapeutics Holdings Inc over the next 12 months, ranging from a $27.00 high to a $9.00 low.
Is ARCT stock a Buy, Sell or Hold right now?+
The current consensus is Moderate Buy. Of the 8 analyst ratings, 6 are Buy or Strong Buy, 2 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for ARCT?+
The Street-high target is $27.00 (Freedom Broker), and the Street-low is $9.00 (HC Wainwright & Co.). The average of all 7 active targets is $21.00.
How many Wall Street analysts cover ARCT?+
8 analysts have an active rating on Arcturus Therapeutics Holdings Inc, and 7 firms carry a live 12-month price target.
Who is the most accurate analyst covering ARCT?+
Among analysts who currently cover ARCT, Mayank Mamtani of B. Riley Securities has the strongest overall Quantellect track record (Rank #41). Their current call is Buy with a $22.00 target.
What is Arcturus Therapeutics Holdings Inc's projected EPS for next quarter?+
The consensus estimate is $-0.90 per share (range $-1.55 – $-0.26) across 10 analysts. Full-year EPS is projected at $-3.42, rising to $-3.61 the following year.
How much revenue is Arcturus Therapeutics Holdings Inc expected to report next quarter?+
Consensus revenue is $5.7M (range $1.9M – $19.7M). Full-year revenue is projected at $18.6M, growing to $29.6M next year.
Have analysts been upgrading or downgrading ARCT lately?+
As of Sep, 6 of 8 firms rate ARCT a Buy (2 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their ARCT calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
